Barclays Maintains Overweight on Nurix Therapeutics, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Nurix Therapeutics (NASDAQ:NRIX) and raises the price target from $20 to $31.
July 15, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Peter Lawson has maintained an Overweight rating on Nurix Therapeutics and increased the price target from $20 to $31.
The increase in the price target from $20 to $31 by a reputable analyst at Barclays is a strong positive signal for investors. This suggests confidence in the company's future performance and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100